Discovery and implementation of transcriptional biomarkers of synthetic LXR agonists in peripheral blood cells

Elizabeth A. DiBlasio-Smith; Maya Arai; Elaine Quinet; Mark J. Evans; Tad Kornaga; Michael Basso; Liang Chen; Irene Feingold; Anita Halpern; Qiang-Yuan Liu; Ponnal Nambi; Dawn Savio; Shuguang Wang; William Mounts; Jennifer A. Isler; Anna M. Slager; Michael E. Burczynski; Andrew J. Dorner; Edward R. LaVallie

doi:10.1186/1479-5876-6-59

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

Peripheral blood cells express LXRalpha and LXRbeta, and respond to LXR agonist treatment by time- and dose-dependently inducing LXR target genes. Transcript levels of LXR target genes in peripheral blood are relevant and useful biological indicators for clinical development of synthetic LXR modulators.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

DiBlasio-Smith et al. (2008) studied this question.

synapsesocial.com/papers/69ddb24ee02db3e29db0bd1b https://doi.org/10.1186/1479-5876-6-59

View Full Paper

Ask AI

Bookmark

Share

Discovery and implementation of transcriptional biomarkers of synthetic LXR agonists in peripheral blood cells

Ask about this paper

Abstract

Discussion

Cite This Study

Discovery and implementation of transcriptional biomarkers of synthetic LXR agonists in peripheral blood cells

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading